Literature DB >> 6809627

Human immune response to various doses of group Y and W135 meningococcal polysaccharide vaccines.

J M Griffiss, B L Brandt, D D Broud.   

Abstract

A divalent vaccine containing equal weights of Neisseria meningitidis group Y and group W135 capsular polysaccharides was inoculated subcutaneously into groups of 32 military recruit volunteers at doses of 10, 25, 50, and 100 micrograms in 10-microliter/microgram volumes. At 4 weeks, the two higher doses induced significantly greater binding antibody responses than did the two lower doses. Differences in response were not found between the two higher doses or between the two lower doses. An additional 32 volunteers received a dose of 25 micrograms in a 20-microliter/microgram volume. Binding antibody response to this vaccine did not differ from the response to doses of 10 and 25 microgram in 10-microliter/microgram volumes. In contrast, bactericidal antibody responses did not differ among doses. Bactericidal antibody was induced in 100% of individuals with low (greater than 4 log2) preexisting serum bactericidal activity, regardless of dose. Bactericidal antibody nonresponse was restricted to individuals with high preexisting serum bactericidal titers. The discrepant dose response between binding and bactericidal antibody resulted from the induction of nonlytic antibody by the higher doses. We conclude that there are no advantages to doses in excess of 5 micrograms of these two chemically similar polysaccharides for the target population of young adult military recruits.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6809627      PMCID: PMC347513          DOI: 10.1128/iai.37.1.205-208.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  5 in total

1.  Clinical and serological evaluation of a meningococcal polysaccharide vaccine groups A, C, and Y.

Authors:  J D Farquhar; W A Hankins; A N Desanctis; J L Demeio; D P Metzgar
Journal:  Proc Soc Exp Biol Med       Date:  1978-01

2.  Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens.

Authors:  G R Siber; P H Schur; A C Aisenberg; S A Weitzman; G Schiffman
Journal:  N Engl J Med       Date:  1980-07-24       Impact factor: 91.245

3.  Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults.

Authors:  J M Griffiss; B L Brandt; P L Altieri; G B Pier; S L Berman
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

4.  Cutaneous reactions and antibody response to meningococcal group C polysaccharide vaccines in man.

Authors:  M S Artenstein; R Gold; J G Zimmerly; F A Wyle; W C Branche; C Harkins
Journal:  J Infect Dis       Date:  1970-04       Impact factor: 5.226

5.  Antibody responses to meningococcal polysaccharide vaccines.

Authors:  B L Brandt; M S Artenstein; C D Smith
Journal:  Infect Immun       Date:  1973-10       Impact factor: 3.441

  5 in total
  11 in total

Review 1.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 2.  Review of meningococcal vaccines with updates on immunization in adults.

Authors:  Yorgo C Zahlanie; Moza M Hammadi; Soha T Ghanem; Ghassan S Dbaibo
Journal:  Hum Vaccin Immunother       Date:  2014-02-05       Impact factor: 3.452

Review 3.  Meningococcal glycoconjugate vaccines.

Authors:  Roberto Gasparini; Donatella Panatto
Journal:  Hum Vaccin       Date:  2011-02-01

4.  Comparison of radioimmunoassay and enzyme-linked immunosorbent assay in measurement of antibodies to Neisseria meningitidis group A capsular polysaccharide.

Authors:  E C Beuvery; M H Kayhty; A B Leussink; V Kanhai
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

5.  Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine.

Authors:  C A Fijen; E J Kuijper; M Drogari-Apiranthitou; Y Van Leeuwen; M R Daha; J Dankert
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

6.  Activation of murine B lymphocytes by Neisseria meningitidis and isolated meningococcal surface antigens.

Authors:  J Melancon; R A Murgita; I W Devoe
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

7.  Epitope specificities of the group Y and W-135 polysaccharides of Neisseria meningitidis.

Authors:  Samuel L Moore; Catherine Uitz; Chang-Chun Ling; David R Bundle; Peter C Fusco; Francis Michon
Journal:  Clin Vaccine Immunol       Date:  2007-09-05

8.  Safety and immunogenicity of a group 29E meningococcal capsular polysaccharide vaccine in adults.

Authors:  J M Griffiss; B L Brandt; P L Altieri; G B Pier; S L Berman
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

9.  Elaboration of a 3.6-kilodalton lipooligosaccharide, antibody against which is absent from human sera, is associated with serum resistance of Neisseria gonorrhoeae.

Authors:  H Schneider; J M Griffiss; R E Mandrell; G A Jarvis
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

10.  Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda.

Authors:  Philippe J Guerin; Lisbeth M Naess; Carole Fogg; Einar Rosenqvist; Loretxu Pinoges; Francis Bajunirwe; Carolyn Nabasumba; Ray Borrow; Leif O Frøholm; Salah Ghabri; Vincent Batwala; Rogers Twesigye; Ingeborg S Aaberge; John-Arne Røttingen; Patrice Piola; Dominique A Caugant
Journal:  PLoS Negl Trop Dis       Date:  2008-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.